The number of British people suffering from breast cancer is increasing at a rate of 2.7% per year, according to new figures, and the NHS will have to spend £8bn more on new drugs by 2020-21.
It is expected that about 40,000 breast cancer patients will die from the disease in the UK by the end of this decade, which is more than double the current rate of 1.4%.
This compares with the UK average of about 5,000 deaths per year.
The National Health Service (NHS) said the figures showed that the NHS has a “massive” job of tackling the growing threat of breast cancer, and called on the Government to continue to support breast cancer research.
The figures also revealed that about 30,000 women and children will die of breast and ovarian cancer in the next decade, and that the number of new cases is expected to increase by 5% by 2020.
The NHS is currently spending £2.8bn on drugs to treat the disease.
A spokesperson for the NHS said: “The NHS has made a significant investment in cancer research over the last five years, but this funding is not sufficient to meet the demand for treatments and we are working to increase the pace of investment.”
“We are seeing an increase in breast cancer cases, particularly among the older age groups.”
While this increase is concerning, it is not unusual.
“We have been investing in new drugs and treatment for decades and we need to keep doing so to meet future growth.”
If the NHS’s funding does not keep pace with this, we will have a massive job of combating the growing cancer threat to the UK.
“The figures are likely to increase pressure on the UK Government to invest more in the NHS.
The latest figures will also raise concerns about the quality of the drugs being developed by the NHS, as well as the long-term safety of the new treatments.
The drugs being tested are being developed with support from the UK’s largest biotechnology firm, GW Pharmaceuticals.
“GW Pharmaceutical is committed to delivering the best value for patients, and we look forward to continuing to work closely with the NHS to ensure that the best possible products are developed for the best benefit for patients.” “
A spokesperson from the Royal College of Surgeons of England said: It is important to recognise that this is a very large and very difficult target to meet. “
GW Pharmaceutical is committed to delivering the best value for patients, and we look forward to continuing to work closely with the NHS to ensure that the best possible products are developed for the best benefit for patients.”
A spokesperson from the Royal College of Surgeons of England said: It is important to recognise that this is a very large and very difficult target to meet.
“However, as a medical profession we have to do our best and the best we can is to keep our focus on patients, the treatment they need and the long term impact they have on their health.”
Breast cancer is the second leading cause of death in the country, after lung cancer.
The Government has pledged to invest £3bn over the next five years on breast cancer treatment, which could mean an increase of £2bn by 2020, but will require significant funding.
The £2 billion could also come from the Government’s NHS rebate, which was increased to £3.25bn in 2020-17.
The new figures are a further boost to support for the cancer drugs being investigated, with a new study published on Wednesday showing that the new drugs could potentially reduce the number and severity of breast cancers.